Reviva mulls FDA filing to start trial of psoriasis drug after promising preclinical data
Sean Anthony Eddy
- Reviva Pharmaceuticals (NASDAQ:RVPH) said it plans to file an application to the U.S. FDA in 2024 for starting a trial of brilaroxazine after promising preclinical data of the potential psoriasis therapy in a mouse model.
- Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) showed efficacy in the imiquimod-induced psoriatic mouse model, according to the company.
- "The multifaceted activity of brilaroxazine offers the promise to improve the quality of life and provide a novel treatment option for patients with psoriasis, an inflammatory condition stemming from serotonin and dopamine dysfunction," said Reviva's Founder, President and CEO Laxminarayan Bhat.
- Reviva added that lipogel treatment group compared to imiquimod-induced psoriatic group: consistently and significantly lowered Psoriasis Area and Severity Index (PASI) scores on days 3-12, with maximum difference on days 11-12.
- The company noted that it has filed composition of matter patent for brilaroxazine-lipogel and a separate patent for use to treat psoriasis.
- Bhat said that the company intends to file an investigational new drug application (IND) for brilaroxazine lipogel in psoriasis in 2024.